Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

PARIS, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company will present first preclinical results on OX401, its next-generation PARP inhibitor (PARPi), during a poster session at the ESMO-TAT¹ Congress 2020 dedicated to the research on targeted cancer therapies, to be held in Paris, France, on March 2-4, 2020.

“Based on our proprietary platform platON, OX401 benefits from our accumulated experience on the original decoy agonist mechanism that it shares with AsiDNA, our clinical-stage DDR inhibitor. We are excited to present the first results on OX401, including its high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells,” said Françoise Bono, Chief Scientific Officer of Onxeo. “These data establish OX401 in the current cutting-edge areas of research and open up promising therapeutic prospects, by exploiting both its ability to exhaust the tumor cell without inducing resistance and its value in combination with immunotherapies.”

OX401 is the second candidate sourced from Onxeo’s proprietary platform of decoy agonists, platON. It was optimized to maintain this unique mechanism of action, while specifically targeting PARP and immune response. Its properties position OX401 at the crossroads of two of the most active areas in oncology, DNA damage repair and immunotherapy.

Poster presentation: OX401, a new generation of PARP interfering drug for cancer treatment

Poster ID: 21P (ID 224)

Date: Monday, March 2, 2020 - 5:30 pm CET

Location: Palais des congrès – Place de la porte Maillot – Paris (France) - Hall Bordeaux

      >      Access the poster

For further information, visit the ESMO Targeted Anticancer Therapies Congress 2020 website

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.